Source: China – South China Morning PostAmerican pharmaceutical giant Pfizer’s up to US$7.3 billion acquisition of next-generation weight loss drugs developer Metsera will encourage more research spending on innovative products in China but is unlikely to draw new players into the fray, according to analysts.
The acquisition of the US company, together with other deals by global pharmaceutical firms, would encourage companies already developing obesity drugs – including those in China – to continue their investments, said the…Read More